Overview

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

Status:
Terminated
Trial end date:
2020-01-23
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
Phase:
Phase 2
Details
Lead Sponsor:
Karyopharm Therapeutics Inc
Karyopharm Therapeutics, Inc